Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia
| Autor: | Peter Greenwald, Ronald Lieberman, David S. Alberts, Catherine M. Tangen, Donna L. Berry, Felicia Parker, Lori M. Minasian, Wael Sakr, Scott M. Lippman, Darien Wood, James R. Marshall, E. David Crawford, David F. Jarrard, Ian M. Thompson, Charles A. Coltman |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Nephrology
Oncology Adult Male medicine.medical_specialty Epidemiology law.invention Placebos Prostate cancer Selenium Randomized controlled trial Double-Blind Method law Internal medicine medicine Anticarcinogenic Agents Humans High-grade prostatic intraepithelial neoplasia Aged Neoplasm Staging Gynecology Aged 80 and over Prostatic Intraepithelial Neoplasia Intraepithelial neoplasia Clinical Trials as Topic business.industry Cancer Prostatic Neoplasms Middle Aged medicine.disease Clinical trial Research Design Chemoprophylaxis Dietary Supplements business |
| Zdroj: | Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 15(8) |
| ISSN: | 1055-9965 |
| Popis: | High-grade prostatic intraepithelial neoplasia (HGPIN) is generally regarded as a premalignant lesion that progresses toward prostate cancer. In light of the significant sequelae of prostate cancer treatment, prevention is desirable, and men with HGPIN would be suitable, high-risk subjects. There is in vitro, in vivo, epidemiologic, and human experimental evidence that selenium supplementation may protect against prostate cancer. This article introduces the rationale for, and progress to date, of a double-blind, randomized, placebo-controlled trial of selenium supplementation (200 μg/d in the form of selenomethionine), to prevent the development of prostate cancer among men with HGPIN. The trial, Southwest Oncology Group Protocol 9917, funded by a National Cancer Institute program supporting pivotal prevention trials has registered 537 patients and has randomized >380 to date. Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009. (Cancer Epidemiol Biomarkers Prev 2006;15(8):1479–84) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|